Artrodar®50mg (diacerein): New restrictions of use to limit the risk of severe diarrhoea and effects on the liver

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 12 February 2015

Description:

A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of the risk of severe diarrhoea and hepatotoxicity with the osteoarthritis medication, Artrodar® (diacerein). The use has been restricted to minimise these risks, including tightening of indication and recommending a lower starting dose.The package inserts for Artrodar® will be updated by TRB Chemedica Malaysia Sdn. Bhd.to reflect these safety changes. Please refer to the DHPC for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA